Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Clinical Trials

Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-11-16

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 62

Registration Number: NCT00400218

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Atenolol
Drug: Hydrochlorothiazide (HCTZ))
Drug: Valsartan

First Posted Date: 2006-11-07

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis

Target Recruit Count: 30

Registration Number: NCT00396656

Locations: 🇨🇭
Novartis Pharma Ag, Basel, Switzerland

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Phase 2

Terminated

Conditions: Pre-diabetes
Pre-hypertension

Interventions: Drug: losartan, hydrochlorothiazide

First Posted Date: 2006-10-16

Last Posted Date: 2015-05-19

Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Target Recruit Count: 1

Registration Number: NCT00388388

Locations: 🇨🇦
Cardiovascular Prevention Centre, Jewish General Hospital, Montreal, Quebec, Canada

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Valsartan
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2006-10-11

Last Posted Date: 2014-02-10

Lead Sponsor: Novartis

Target Recruit Count: 601

Registration Number: NCT00386607

Locations: 🇳🇱
Investigative Centers, Netherlands, Netherlands

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil
Drug: Hydrochlorothiazide

First Posted Date: 2006-10-04

Last Posted Date: 2008-03-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 1979

Registration Number: NCT00383929

Locations: 🇩🇪
Research SIte, Hann, Germany
🇬🇧
Research Site, Wokingham, United Kingdom

A Study in People With Mild Hypertension

Phase 2

Completed

Conditions: Mild Hypertension

First Posted Date: 2006-09-12

Last Posted Date: 2007-05-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT00374855

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Stockholm, Sweden